Long-Term Treatment with Bortezomib Induces Specific Methylation Changes in Differentiated Neuronal Cells

Long-Term Treatment with Bortezomib Induces Specific Methylation Changes in Differentiated Neuronal Cells

Bortezomib (BTZ) is proteasome inhibitor, effectively used in the treatment of multiple myeloma, but frequently discontinued due to peripheral neuropathy, which develops in patients after consecutive treatment cycles. The molecular mechanisms affected by BTZ in neuronal cells, which result in neurop...

Full description

Bibliographic Details
Main Authors: Karolina Łuczkowska, Olga Taryma-Leśniak, Jan Bińkowski, Katarzyna E. Sokołowska, Dominik Strapagiel, Justyna Jarczak, Edyta Paczkowska, Bogusław Machaliński, Tomasz K. Wojdacz
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Cancers
Subjects:
multiple myeloma
peripheral neuropathy
bortezomib
LUHMES
methylation
epigenetics
Online Access:https://www.mdpi.com/2072-6694/14/14/3402

Internet

https://www.mdpi.com/2072-6694/14/14/3402

Similar Items